Abstract
Giant-cell arteritis (GCA) is the most common vasculitis affecting large vessels in the elderly. It is associated with ischemic events that account for important disability. Despite the increasing insight in the mechanisms involved in the arterial wall inflammation, the events that lead to eventual occlusion of the vessels lumen are unknown. Cohort studies on risk factors for ischemic events and aspirin efficiency in GCA provide inconsistent results. Corticosteroids, which prevent the worsening or the recurrence of ischemia in the majority of patients, are slow-acting and not effective in all patients. The interaction between circulating activated platelets and leukocytes contributes in acute myocardial infarction and other ischemic diseases to determine the prothrombotic and inflammatory characteristics of blood cells. The activation of circulating platelets, their interaction with leukocytes and the expression of tissue factor by circulating leukocytes frequently occur in patients with GCA. The molecular characterization of the cross-talk between blood cells and the inflamed vessel wall could yield molecular targets for novel therapeutics, more effective than aspirin in preventing ischemic events and more specific than steroids in their treatment.
Keywords: Giant-cell arteritis, polymyalgia rheumatica, platelets, neutrophils, drug design.
Current Pharmaceutical Design
Title:Targeting Platelet-Neutrophil Interactions in Giant-Cell Arteritis
Volume: 20 Issue: 4
Author(s): Mattia Baldini, Angelo A. Manfredi and Norma Maugeri
Affiliation:
Keywords: Giant-cell arteritis, polymyalgia rheumatica, platelets, neutrophils, drug design.
Abstract: Giant-cell arteritis (GCA) is the most common vasculitis affecting large vessels in the elderly. It is associated with ischemic events that account for important disability. Despite the increasing insight in the mechanisms involved in the arterial wall inflammation, the events that lead to eventual occlusion of the vessels lumen are unknown. Cohort studies on risk factors for ischemic events and aspirin efficiency in GCA provide inconsistent results. Corticosteroids, which prevent the worsening or the recurrence of ischemia in the majority of patients, are slow-acting and not effective in all patients. The interaction between circulating activated platelets and leukocytes contributes in acute myocardial infarction and other ischemic diseases to determine the prothrombotic and inflammatory characteristics of blood cells. The activation of circulating platelets, their interaction with leukocytes and the expression of tissue factor by circulating leukocytes frequently occur in patients with GCA. The molecular characterization of the cross-talk between blood cells and the inflamed vessel wall could yield molecular targets for novel therapeutics, more effective than aspirin in preventing ischemic events and more specific than steroids in their treatment.
Export Options
About this article
Cite this article as:
Baldini Mattia, Manfredi A. Angelo and Maugeri Norma, Targeting Platelet-Neutrophil Interactions in Giant-Cell Arteritis, Current Pharmaceutical Design 2014; 20 (4) . https://dx.doi.org/10.2174/138161282004140213144840
DOI https://dx.doi.org/10.2174/138161282004140213144840 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clozapine Induced Eosinophilia in a Case of Schizoaffective Disorder
Current Psychopharmacology Role of Endothelial Progenitor Cell Mobilization After Percutaneous Angioplasty Procedure
Current Pharmaceutical Design Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold
Current Medicinal Chemistry Monosubstituted Coumarins Inhibit Epinephrine-induced Platelet Aggregation
Cardiovascular & Hematological Agents in Medicinal Chemistry Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology Small-Molecule Chemokine Receptor Antagonists: Potential Targets for Inflammatory and Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews A Role for the Complement System in Rheumatoid Arthritis
Current Pharmaceutical Design Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Advanced Techniques for Imaging the Human Spinal Cord: Review of Literature
Current Medical Imaging Established Treatments of Psoriasis
Current Drug Targets - Inflammation & Allergy Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Role of Redox Homeostasis and Inflammation in the Pathogenesis of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Pharmacotherapeutic Potential of Garlic in Age-Related Neurological Disorders
CNS & Neurological Disorders - Drug Targets Advances in Drug Therapy for Systemic Lupus Erythematosus
Current Medicinal Chemistry Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Design and Synthesis of Novel Coumarin Conjugated Acetamides as Promising Anticancer Agents: An <i>In Silico</i> and <i>In Vitro</i> Approach
Anti-Cancer Agents in Medicinal Chemistry